SG139618A1 - Influenza vaccine - Google Patents

Influenza vaccine

Info

Publication number
SG139618A1
SG139618A1 SG200702946-5A SG2007029465A SG139618A1 SG 139618 A1 SG139618 A1 SG 139618A1 SG 2007029465 A SG2007029465 A SG 2007029465A SG 139618 A1 SG139618 A1 SG 139618A1
Authority
SG
Singapore
Prior art keywords
influenza
influenza vaccine
relates
monovalent
oil
Prior art date
Application number
SG200702946-5A
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0618195A external-priority patent/GB0618195D0/en
Priority claimed from GB0619090A external-priority patent/GB0619090D0/en
Priority claimed from PCT/EP2006/010439 external-priority patent/WO2008009309A1/en
Priority claimed from GB0623218A external-priority patent/GB0623218D0/en
Priority claimed from GB0623865A external-priority patent/GB0623865D0/en
Priority claimed from GB0625453A external-priority patent/GB0625453D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SG139618A1 publication Critical patent/SG139618A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INFLUENZA VACCINE The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent. Figure 2A.
SG200702946-5A 2006-07-17 2007-04-18 Influenza vaccine SG139618A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US83143706P 2006-07-17 2006-07-17
GB0618195A GB0618195D0 (en) 2006-09-15 2006-09-15 Influenza vaccine
GB0619090A GB0619090D0 (en) 2006-09-27 2006-09-27 Influenza vaccine
PCT/EP2006/010439 WO2008009309A1 (en) 2006-07-17 2006-10-27 Influenza vaccine
GB0623218A GB0623218D0 (en) 2006-11-21 2006-11-21 Influenza vaccine
GB0623865A GB0623865D0 (en) 2006-11-29 2006-11-29 Influenza vaccine
GB0625453A GB0625453D0 (en) 2006-12-20 2006-12-20 Influenza vaccine

Publications (1)

Publication Number Publication Date
SG139618A1 true SG139618A1 (en) 2008-02-29

Family

ID=39111000

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200702946-5A SG139618A1 (en) 2006-07-17 2007-04-18 Influenza vaccine

Country Status (1)

Country Link
SG (1) SG139618A1 (en)

Similar Documents

Publication Publication Date Title
MX2009000660A (en) Influenza vaccine.
TW200722101A (en) Novel composition
Garçon et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Weinberger Adjuvant strategies to improve vaccination of the elderly population
BRPI0621886A8 (en) monovalent influenza vaccine composition, kit, method for producing an influenza vaccine composition for a pandemic or prepandemic situation, and uses of an influenza virus antigen or antigen preparation thereof and an adjuvant in an oil-in-water emulsion, a pandemic influenza virus antigen or antigen preparation of the influenza virus hemagglutinin antigen, a pandemic influenza virus or antigenic preparation thereof, and an oil-in-emulsion adjuvant water and an antigen or antigen preparation of a first strain of influenza
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
EP2455101A3 (en) Influenza vaccine with oil-in-water emulsion adjuvant
NO20091022L (en) Vaccine comprising an oil in water emulsion adjuvant
NZ568210A (en) Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
BR112013005427A2 (en) immunogenic composition, vaccine, method for treating or preventing disease, and for preparing the immunogenic composition or vaccine, use of the vaccine, and pharmaceutical composition.
Parodi et al. Inactivated influenza vaccines: recent progress and implications for the elderly
Morçӧl et al. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice
BR112014023283A8 (en) IMMUNOGENIC COMPOSITION, SECOND IMMUNOGENIC COMPOSITION, AND METHOD FOR PREVENTION AND/OR TREATMENT AGAINST INFLUENZA DISEASE
SG139618A1 (en) Influenza vaccine
NZ583377A (en) Method of eliciting an immune response against pandemic influenza virus
Sisteré-Oró et al. Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
SG160386A1 (en) Novel composition
CY1115921T1 (en) Flu vaccine
UY29429A1 (en) IMMUNOGENIC COMPOSITION CONTAINING VIRUSES OF THE FLU OR ANCIENT PREPARATION OF THE SAME, ITS USES AND PREPARATION PROCEDURES.
MX2009010963A (en) Oil-in-water emulsion influenza vaccine.
BRPI0609516B8 (en) use of an influenza virus or antigenic preparation thereof
Fisher et al. Adjuvanted vaccines against influenza in the elderly
Acevedo et al. Adjuvants: an essential component of neisseria vaccines
Acevedo et al. Adjuvantes: Un componente esencial de las vacunas de Neisseria
UA91701C2 (en) Monovalent influenza vaccine composition comprising a influenza virus antigen and an oil-in-water emulsion adjuvant